Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement

Annals of Hematology

Volumn 80, Issue 2, 2001, Pages 83-89

  Draube, A ^a   Pfister, R ^a   Vockerodt, M ^a   Schuster, S ^a   Kube, D ^b   Diehl, V ^a   Tesch, H ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

CD138; CDR3 PCR; Immunomagnetic enrichment; MACS; Multiple myeloma

Indexed keywords

ANTIBODY CONJUGATE; IMMUNOGLOBULIN HEAVY CHAIN; OLIGONUCLEOTIDE; SYNDECAN;

ANTIGEN EXPRESSION; ARTICLE; BLOOD; BONE MARROW; CANCER INFILTRATION; CELL CLONE; CELL COUNT; CELL POPULATION; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; IMMUNOGLOBULIN GENE; LEUKAPHERESIS; METHODOLOGY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REPRODUCIBILITY; SAMPLING;

CONSENSUS SEQUENCE; GENE REARRANGEMENT, B-LYMPHOCYTE, LIGHT CHAIN; HUMANS; IMMUNOMAGNETIC SEPARATION; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROTEOGLYCANS; SEQUENCE ANALYSIS; SYNDECAN-1; SYNDECANS;

EID: 0035115702     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770000245     Document Type: Article

References (39)

1. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation
2. Biology of the syndecans: A family of transmembrane heparan sulfate proteoglycans
3. Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: A technique for sequential quantitation of residual disease
4. Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement
5. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients
6. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation
7. Hepatocyte growth factor and its receptor c-met in multiple myeloma
8. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
9. Detection of circulating tumor cells in multiple myeloma by a PCR-based method
10. Syndecans, signaling, and cell adhesion
11. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma
12. Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization
13. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation
14. Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues
15. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells
16. Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V region genes
17. Micromanipulation and PCR analysis of single cells from tissue sections
18. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections
19. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma
20. Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes
21. Normal and clonal B lineage cells can be distinguished by their differential expression of B cell antigens and adhesion molecules in peripheral blood from multiple myeloma (MM) patients - Diagnostic and clinical implications
22. Assessment of IgH PCR strategies in multiple myeloma
23. In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma
24. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage
25. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen
26. B lymphocytes express and lose syndecan at specific stages of differentiation
27. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican
28. Large scale and clinical grade purification of syndecan-1+ malignant plasma cells
29. Clinical utility of immunoglobulin heavy chain gene rearrangement identification for tumour cell detection in multiple myeloma
30. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements
31. Somatic generation of antibody diversity
32. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma
33. Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity
34. Detection of clonal Hodgkin and Reed-Sternberg cells with identical somatically mutated and rearranged VH genes in different biopsies in relapsed Hodgkin's disease
35. CD138 cluster report
36. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1
37. CD34 selections from myeloma peripheral blood cell autografts contain residual tumour cells due to impurity, not to CD34+ myeloma cells
38. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia
39. Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes